53,430 Shares in Bicara Therapeutics Inc. $BCAX Acquired by SCS Capital Management LLC

SCS Capital Management LLC bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 53,430 shares of the company’s stock, valued at approximately $1,586,000.

Several other institutional investors have also recently added to or reduced their stakes in BCAX. Legal & General Group Plc boosted its holdings in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after acquiring an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Bicara Therapeutics in the fourth quarter valued at $45,000. Larson Financial Group LLC boosted its stake in Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after acquiring an additional 4,585 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Morgan Stanley lifted their target price on Bicara Therapeutics from $37.00 to $39.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. Guggenheim initiated coverage on Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 price target on the stock. Finally, Wells Fargo & Company lifted their price target on Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bicara Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $32.73.

Bicara Therapeutics Price Performance

NASDAQ BCAX opened at $24.28 on Monday. Bicara Therapeutics Inc. has a 52-week low of $10.30 and a 52-week high of $30.99. The business’s 50-day moving average price is $26.15 and its 200 day moving average price is $21.84. The firm has a market cap of $1.61 billion, a P/E ratio of -7.83 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.82). As a group, analysts anticipate that Bicara Therapeutics Inc. will post -3.45 earnings per share for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other news, COO Ryan Cohlhepp sold 28,214 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $28.98, for a total transaction of $817,641.72. Following the completion of the sale, the chief operating officer owned 182,177 shares in the company, valued at $5,279,489.46. This represents a 13.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 10,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.98, for a total value of $279,800.00. Following the sale, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at approximately $10,133,012.96. This represents a 2.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 117,200 shares of company stock worth $3,267,100. 13.80% of the stock is currently owned by insiders.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.